Brief: Anthera announces termination of blisibimod partnership in Japan by Zenyaku

Anthera Pharmaceuticals

14/09/2015 21:30

Sept 14 (Reuters) - Anthera Pharmaceuticals Inc  ANTH.O : 
 * Announces termination of blisibimod partnership in Japan by zenyaku 
 * Says Anthera will regain all worldwide rights for blisibimod without cost 
 * Says no patients were enrolled in the bright-sc study or any other clinical 
   study in Japan 
 * Says Zenyaku is required to continue various funding obligations during the 
   termination period 
 * Says "termination was "at will" and alleged no breach of the license 
   agreement by Anthera" 
 * Says no effect on blisibimod lupus program or sollpura development program 
 * At the time of the notification, Zenyaku had not purchased any blisibimod 
   product from Anthera 
 * Got termination notice from development partner,Zenyaku, terminating 
   collaboration and license agreement effective January 7, 2016 
 
* Source text for Eikon  ID:nGNXVEKSRa  
 
* Further company coverage  ANTH.O  ((Bengaluru Newsroom; +1 646 223 8780))